A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer.

Specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals.

Researchers have now identified a type of skin cell as the target of the virus in humans.

This study, from the Perelman School of Medicine at the University of Pennsylvania, establishes a new way to investigate this type of oncogenic viral infection and identifies a potential therapeutic agent against Merkel cell polyomavirus infection.

Merkel cell carcinoma, which metastasises rapidly, is one of the most aggressive skin cancers, with a mortality rate of 33 percent, exceeding that of melanoma, and a 45 percent five-year survival rate.

Given these dire statistics, researchers are keen to find better treatments.

Senior author Jianxin You, PhD, an associate professor of Microbiology, published her results this month in Cell Host & Microbe. "We established a cell culture model for Merkel cell polyomavirus infection, which will help us find how this DNA virus causes cancer," You said.

Using this model, the team discovered that the activation of special enzymes called matrix metalloproteinases by a cellular signalling pathway involving the WNT and β-catenin proteins stimulate Merkel cell polyomavirus infection. "This suggests that Merkel cell carcinoma risk factors such as ultraviolet radiation and aging, which are known to stimulate the expression of these metalloproteinase enzymes, may promote viral infection and thus drive the development of cancer."

These enzymes work in wound healing to re-engineer the skin as it heals.

For example, if the skin is harmed by excessive sunlight, this stimulates the WNT/β-catenin signalling pathway, which in turn activates the metalloproteinase enzymes to be made.

In the wound-healing process, these enzymes "chew up" the extracellular matrix of affected cells.

This could allow viruses to enter the cells of the dermis skin layer, surmise the researchers.

The Merkel cell polyomavirus is an abundant virus frequently found on healthy human skin.

Excessive exposure to sunlight and ultraviolet radiation, immune suppression, and advanced age are the most important risk factors for Merkel cell carcinoma.

Although the exact function of Merkel cells, found in the lower part of the skin epidermis, is unknown, they are thought to be nerve-associated cells involved in light touch sensation.

This study also found that the FDA-approved drug trametinib for melanoma and other cancers blocks viral infection by stopping Merkel cell polyomavirus transcription and replication.

Low doses of trametinib wiped out viral infection in the cell culture model developed by first author Wei Liu, PhD, a senior postdoctoral fellow in the You laboratory.

In addition, normal control cells were not affected by trametinib, giving hope to the fact that this drug might be able to be used with little side effects for reducing the viral load in immuno-compromised patients and the goal of preventing the development of Merkel cell carcinoma.

"Building on this novel cell culture model for Merkel cell polyomavirus infection, we would like to establish an animal model to elucidate the mechanisms by which Merkel cell polyomavirus infection leads to the highly aggressive Merkel cell carcinoma," Liu said.

For more on Merkel cell carcinoma and treatment, you can watch an interview with Dr Paul Nghiem from the University of Washington, recorded at AACR 2016, in which he discusses pembrolizumab as a potential therapy.

Source: Cell Host and Microbe